Figure 4.

In vivo GdBNCT therapy for treating HTB-43 H&N tumors. 48 Mice were divided into eight groups, including a blank control (n = 6), control+NR (n = 6), doxorubicin (DOX, an anticancer chemotherapy drug)-treated group (n = 6), BPA-F 24 h+NR (n = 6), BPA-F 1 h+NR (n = 6), anti-EGFR-Ce¹⁰B₆ NPs+NR (n = 6), and anti-EGFR-Gd¹⁰B₆ NPs+NR (n = 6). (a) Biodistribution of both gadolinium and boron elements in mice injected with anti-EGFR-Gd¹⁰B₆ NPs as a function of time. (b) Tumor growth curves for different treatment groups as a function of treatment days after neutron irradiation. (c) Survival rates of various treated mice groups. (d) Photographs of HTB-43 tumor-bearing mice from eight groups during the 21 days period after treatments. The doses of BPA-F, anti-EGFR-Gd₂O₃ NPs, anti-EGFR-Ce¹⁰B₆ NPs, and anti-EGFR-Gd¹⁰B₆ NPs, are the same, i.e., 50 mg/kg, which is equivalent to the amounts of (36.15 mg of Gd/kg and 13.85 mg of ¹⁰B/kg) for Gd¹⁰B₆, (15 mg of ¹⁰B/kg) for Ce¹⁰B₆, and (43.35 mg of Gd/kg) for Gd₂O₃ nanoparticles, respectively.